Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
In a shocking failure, Virios Therapeutics announced this morning pre-market that topline results from its FORTRESS (Fibromyalgia Outcome…
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
Mayo Clinic, Hibiscus BioVentures (Hibiscus), and Innoforce have announced the formation of Mayflower BioVentures, a cell and gene…
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
Ocugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial
Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…
EF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
Legend Biotech Appoints Dr. Guowei Fang As Head of Global Research and Early Development
Global biotechnology company Legend Biotech Corporation (NASDAQ: LEGN) announced today that Guowei Fang, Ph.D. will take over as…
2seventy bio Secure $170 Million Extending Cash Runway Into 2025
2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
Inhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference
Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be…
Celyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
With the appointments of these experts, the firm has added to its industry knowledge, including Chief Scientific Officer…
Nasdaq Biotechnology Index Adds Quantum-Si (Nasdaq: QSI) Life Sciences Company
Quantum-Si (Nasdaq: QSI), a life science instrumentation firm commercializing a distinctive protein sequencing technology, has been added to…
Sigilon Therapeutics Provides Update on Strategic Reprioritization
The company will continue to focus on platform optimization, with a particular emphasis on MPS-1 and diabetes. The…
MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
Biopharma MacroGenics, Inc. (NASDAQ: MGNX) announced that the final overall survival (OS) analysis did not demonstrate a statistically…
Infinity Pharmaceuticals Add 2 New Members to Board of Directors
Clinical-stage biotech Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced the change of 2 new Board of Directors roles including…